| 000 | 01843 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516033407.0 | ||
| 264 | 0 | _c20111121 | |
| 008 | 201111s 0 0 eng d | ||
| 022 | _a1477-0970 | ||
| 024 | 7 |
_a10.1177/1352458511401943 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPatti, F | |
| 245 | 0 | 0 |
_aQuality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. _h[electronic resource] |
| 260 |
_bMultiple sclerosis (Houndmills, Basingstoke, England) _cAug 2011 |
||
| 300 |
_a991-1001 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xadministration & dosage |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCognition Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aDepression _xdrug therapy |
| 650 | 0 | 4 |
_aFatigue _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aInterferon beta-1a |
| 650 | 0 | 4 |
_aInterferon-beta _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xcomplications |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aAmato, M P | |
| 700 | 1 | _aTrojano, M | |
| 700 | 1 | _aBastianello, S | |
| 700 | 1 | _aTola, M R | |
| 700 | 1 | _aPicconi, O | |
| 700 | 1 | _aCilia, S | |
| 700 | 1 | _aCottone, S | |
| 700 | 1 | _aCentonze, D | |
| 700 | 1 | _aGasperini, C | |
| 773 | 0 |
_tMultiple sclerosis (Houndmills, Basingstoke, England) _gvol. 17 _gno. 8 _gp. 991-1001 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/1352458511401943 _zAvailable from publisher's website |
| 999 |
_c20768091 _d20768091 |
||